semaglutide and spleen Females are protected from semaglutide-induced muscle loss in ob/ob mice Semaglutide GLP-1 Weight Loss Injections

Injections, drops, or lozenges

The medication's extended half-life of approximately one week allows for once-weekly subcutaneous administration, maintaining steady blood levels that support consistent drug activity

Some risk factors cannot be changed, such as age and genetics

Semaglutide is the active ingredient in popular weight loss medications like Wegovy

GLP-1 Medications and Gastric Emptying GLP-1 receptor agonists are known to slow gastric emptying, which contributes to their effectiveness in promoting fullness and reducing appetite

Compounded medications are not FDA-approved and may carry different risks than FDA-approved medications